KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Profit After Tax (2016 - 2025)

Inovio Pharmaceuticals' Profit After Tax history spans 16 years, with the latest figure at -$45.5 million for Q3 2025.

  • For Q3 2025, Profit After Tax fell 80.79% year-over-year to -$45.5 million; the TTM value through Sep 2025 reached -$108.1 million, up 4.24%, while the annual FY2024 figure was -$107.3 million, 20.62% up from the prior year.
  • Profit After Tax for Q3 2025 was -$45.5 million at Inovio Pharmaceuticals, down from -$23.5 million in the prior quarter.
  • Across five years, Profit After Tax topped out at -$19.4 million in Q4 2024 and bottomed at -$108.5 million in Q2 2022.
  • The 5-year median for Profit After Tax is -$37.8 million (2022), against an average of -$48.1 million.
  • The largest annual shift saw Profit After Tax tumbled 413.85% in 2021 before it skyrocketed 67.25% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$106.9 million in 2021, then soared by 49.07% to -$54.5 million in 2022, then soared by 54.09% to -$25.0 million in 2023, then rose by 22.48% to -$19.4 million in 2024, then tumbled by 134.74% to -$45.5 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Profit After Tax are -$45.5 million (Q3 2025), -$23.5 million (Q2 2025), and -$19.7 million (Q1 2025).